Overview
Comprehensive assessment of Parkinson's Disease (PD) requires validated rating scales that capture motor symptoms, non-motor features, functional disability, and quality of life. This page documents the key assessment instruments used in PD clinical care and research.
Motor Assessment Scales
Hoehn and Yahr Scale
The Hoehn and Yahr scale is the most widely used clinical rating scale for Parkinsonism, originally published in 1967 and modified subsequently. It provides a global measure of disease severity based on clinical staging.
| Stage | Description |
|-------|-------------|
| 0 | No signs of disease |
| 1 | Unilateral disease |
| 1.5 | Unilateral and axial involvement |
| 2 | Bilateral disease, without impairment of balance |
| 2.5 | Mild bilateral disease, with recovery on pull test |
| 3 | Mild to moderate bilateral disease; some postural instability; physically independent |
| 4 | Severe disability; still able to walk or stand unassisted |
| 5 | Wheelchair bound or bedridden unless aided |
Clinical Utility: The Hoehn and Yahr scale is simple to administer and correlates with dopaminergic neuron loss as measured by SPECT imaging. It remains a standard outcome measure in clinical trials despite its categorical nature.
Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
The Movement Disorder Society revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is the gold standard for comprehensive PD assessment. Released in 2008, it addresses limitations of the original 1987 UPDRS.
...Overview
Comprehensive assessment of Parkinson's Disease (PD) requires validated rating scales that capture motor symptoms, non-motor features, functional disability, and quality of life. This page documents the key assessment instruments used in PD clinical care and research.
Motor Assessment Scales
Hoehn and Yahr Scale
The Hoehn and Yahr scale is the most widely used clinical rating scale for Parkinsonism, originally published in 1967 and modified subsequently. It provides a global measure of disease severity based on clinical staging.
| Stage | Description |
|-------|-------------|
| 0 | No signs of disease |
| 1 | Unilateral disease |
| 1.5 | Unilateral and axial involvement |
| 2 | Bilateral disease, without impairment of balance |
| 2.5 | Mild bilateral disease, with recovery on pull test |
| 3 | Mild to moderate bilateral disease; some postural instability; physically independent |
| 4 | Severe disability; still able to walk or stand unassisted |
| 5 | Wheelchair bound or bedridden unless aided |
Clinical Utility: The Hoehn and Yahr scale is simple to administer and correlates with dopaminergic neuron loss as measured by SPECT imaging. It remains a standard outcome measure in clinical trials despite its categorical nature.
Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
The Movement Disorder Society revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is the gold standard for comprehensive PD assessment. Released in 2008, it addresses limitations of the original 1987 UPDRS.
Structure:
- Part I: Non-motor experiences of daily living (13 items, 0-52 points)
- Part II: Motor experiences of daily living (13 items, 0-52 points)
- Part III: Motor examination (33 items, 0-132 points)
- Part IV: Motor complications (6 items, 0-24 points)
Total Score Range: 0-260 (higher = more severe)
Key Improvements over Original UPDRS:
- Expanded non-motor symptom coverage
- Better psychometric properties
- Clinically meaningful rating anchor points
- Validated for telehealth administration
See: [MDS-UPDRS official scale](https://www.movementdisorders.org/MDS.htm)
Schwab and England Activities of Daily Living Scale
The Schwab and England scale provides a quick global measure of functional independence:
- 100% — Completely independent
- 90% — Completely independent with difficulty
- 80% — Somewhat independent, no assistance needed
- 70% — Not completely independent
- 60% — Requires some assistance
- 50% — Much assistance required
- 40% — Severe disability
- 30% — Nearly all activities require assistance
- 20% — Barely independent
- 10% — Completely dependent
Cognitive Assessment Instruments
Montreal Cognitive Assessment (MoCA)
The MoCA is a brief 30-point cognitive screening test sensitive to mild cognitive impairment in PD:
- Visuospatial/executive: 5 points
- Naming: 3 points
- Memory: 5 points
- Attention: 6 points
- Language: 3 points
- Abstraction: 2 points
- Orientation: 6 points
Cutoff: <26 suggests cognitive impairment
Parkinson's Disease Cognitive Rating Scale (PD-CRS)
Specifically designed for PD, the PD-CRS assesses:
- Frontally-mediated tasks
- Visuospatial abilities
- Memory
- Attention
Mattis Dementia Rating Scale (DRS-2)
Comprehensive assessment of multiple cognitive domains, sensitive to executive dysfunction in PD.
Non-Motor Symptom Assessments
Parkinson's Disease Sleep Scale (PDSS)
The PDSS assesses nocturnal and sleep-related symptoms:
- Quality of sleep
- Nocturnal restlessness
- Nighttime hallucinations
- Sleep apnea symptoms
Epworth Sleepiness Scale (ESS)
Measures daytime sleepiness, important given the high prevalence of sleep disorders in PD.
Beck Depression Inventory (BDI-II)
Gold standard for depression screening in PD.
State-Trait Anxiety Inventory (STAI)
Anxiety is common in PD and impacts quality of life.
Sniffin' Sticks Test
Olfactory dysfunction is one of the earliest and most prevalent non-motor symptoms in PD:
- Threshold test
- Discrimination test
- Identification test
Combined score (TDI): Normal >30.1, hyposmia 16-30.1, anosmia <16
See: [Olfactory testing in PD diagnostics](/mechanisms/olfactory-dysfunction-parkinsons)
REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ)
Useful for identifying REM sleep behavior disorder, a prodromal marker.
Motor-Specific Assessments
Timed Up and Go Test (TUG)
Measures functional mobility:
- Time to stand from seated position
- Walk 3 meters
- Turn around
- Return to seated
PD cutoff: >13.5 seconds suggests fall risk
10-Meter Walk Test
Measures gait velocity, a predictor of disease progression and falls.
Freezing of Gait Questionnaire (FOG-Q)
Specifically assesses freezing of gait, a disabling motor phenomenon in advanced PD.
Pull Test Retropulsion Test
Evaluates postural stability and balance impairment.
Quality of Life Measures
Parkinson's Disease Questionnaire-39 (PDQ-39)
The most widely used PD-specific quality of life measure:
- Mobility (10 items)
- Activities of daily living (6 items)
- Emotional well-being (6 items)
- Stigma (4 items)
- Social support (3 items)
- Cognitions (4 items)
- Communication (3 items)
- Bodily discomfort (3 items)
SF-36 Health Survey
Generic quality of life measure for comparison across conditions.
Biomarker Correlations
These clinical scales correlate with objective biomarkers:
- MDS-UPDRS Part III correlates with DaTSPECT imaging
- Olfactory testing correlates with Lewy body pathology burden
- RBD correlates with [alpha-synuclein](/proteins/alpha-synuclein) spread
- Cognitive scores correlate with CSF amyloid and [tau](/proteins/tau) biomarkers
Clinical Trial Endpoints
Common primary and secondary endpoints in PD clinical trials:
| Endpoint | Scale | Clinical Meaningfulness |
|----------|-------|------------------------|
| Primary | MDS-UPDRS total | Comprehensive disease impact |
| Primary | ON/OFF time | Motor fluctuation control |
| Secondary | MoCA | Cognitive progression |
| Secondary | PDQ-39 | Quality of life |
| Exploratory | FOG-Q | Freezing assessment |
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Goetz et al., MDS-UPDRS validation (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18836027/)
[Unknown, Hoehn & Yahr original publication (1967) (1967)](https://pubmed.ncbi.nlm.nih.gov/6067256/)
[Unknown, PDQ-39 development and validation (n.d.)](https://pubmed.ncbi.nlm.nih.gov/1376713/)
[Unknown, Sniffin' Sticks normative data (n.d.)](https://pubmed.ncbi.nlm.nih.gov/9702653/)